T‐cell receptor sequencing reveals hepatocellular carcinoma immune characteristics according to Barcelona Clinic liver cancer stages within liver tissue and peripheral blood
Open Access
- 14 November 2023
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 115 (1) , 94-108
Abstract
Analysis of T‐cell receptor (TCR) repertoires in different stages of hepatocellular carcinoma (HCC) might help to elucidate its pathogenesis and progression. This study aimed to investigate TCR profiles in liver biopsies and peripheral blood mononuclear cells (PBMCs) in different Barcelona Clinic liver cancer (BCLC) stages of HCC. Ten patients in early stage (BCLC_A), 10 patients in middle stage (BCLC_B), and 10 patients in late stage (BCLC_C) cancer were prospectively enrolled. The liver tumor tissues, adjacent tissues, and PBMCs of each patient were collected and examined by TCR β sequencing. Based on the ImMunoGeneTics (IMGT) database, we aligned the V, D, J, and C gene segments and identified the frequency of CDR3 sequences and amino acids sequence. Diversity of TCR in PBMCs was higher than in both tumor tissues and adjacent tissues, regardless of BCLC stage and postoperative recurrence. TCR clonality was increased in T cells from peripheral blood in advanced HCC, compared with the early and middle stages. No statistical differences were observed between different BCLC stages, either in tumors or adjacent tissues. TCR clonality revealed no significant difference between recurrent tumor and non‐recurrent tumor, therefore PBMCs was better to be representative of TCR characteristics in different stages of HCC compared to tumor tissues. Clonal expansion of T cells was associated with low risk of recurrence in HCC patients.Keywords
Funding Information
- National Natural Science Foundation of China (81971720, 82370610)
- Science and Technology Planning Project of Guangdong Province (2023A0505050115)
This publication has 41 references indexed in Scilit:
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Characterization of T and B cell repertoire diversity in patients with RAG deficiencyScience Immunology, 2016
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after ImmunotherapyCancer Immunology Research, 2016
- Hydrophobic CDR3 residues promote the development of self-reactive T cellsNature Immunology, 2016
- Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancerOncology Letters, 2016
- CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencingNature Communications, 2016
- Too much of a good thing: Sustained type 1 interferon signaling limits humoral responses to secondary viral infectionEuropean Journal of Immunology, 2016
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanomaJournal for ImmunoTherapy of Cancer, 2015
- Vγ2Vδ2 T Cell Receptor Recognition of Prenyl Pyrophosphates Is Dependent on All CDRsThe Journal of Immunology, 2010
- Regulation and Chance in the Ontogeny of B and T Cell Antigen Receptor RepertoiresImmunologic Research, 2002